CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 491 enrolled
Drug / intervention
Oral rucaparibdrug
Likely dose
Oral rucaparib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01891344
NCT01891344Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

pharmaand GmbH·interventional·Posted Jul 3, 2013·Updated Jun 12, 2023

In Brief

A Phase 2 clinical trial evaluating Oral rucaparib for Ovarian Cancer and 3 related conditions. Completed, enrolled 491 participants across 75 sites in 6 countries.

Detailed Summary

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesAustralia, Canada, France, Spain, United Kingdom, United States
CollaboratorsFoundation Medicine, Myriad Genetics, Inc.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 3, 2013
Enrollment StartOct 30, 2013
Primary CompletionNov 5, 2019
Study CompletionSep 28, 2021
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 13.0 years ago

Interventions

Oral rucaparibdrug

600 mg BID